Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
about
mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.De novo and secondary acute myeloid leukemia in patients over the age of 65: a review of fifty-six successive and unselected cases from a general hospital.Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.Blast crisis in chronic myelogenous leukemia remains a difficult therapeutic challenge.
P2860
Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Treatment of chronic myelogeno ...... ine arabinoside and amsacrine.
@en
type
label
Treatment of chronic myelogeno ...... ine arabinoside and amsacrine.
@en
prefLabel
Treatment of chronic myelogeno ...... ine arabinoside and amsacrine.
@en
P2093
P2860
P1433
P1476
Treatment of chronic myelogeno ...... ine arabinoside and amsacrine.
@en
P2093
Delmas-Marsalet B
P2860
P304
P356
10.3109/10428199309145883
P577
1993-06-01T00:00:00Z